Celcuity opened lower at $63.36, compared with its previous close of $64.32. In the last trading session, the stock traded between $60.97 and $65.81. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Celcuity is now worth
$ 371.89
Giving a profit of
$ 271.89 (271.89%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.17 (-0.26%)
Day High
$65.81
Day Low
$60.97
Day Open
$63.36
Prev Close
$64.32
Volume
7,16,662
1W Return
-7.40%
1M Return
-2.68%
3M Return
-27.17%
6M Return
-48.94%
1Y Return
-18.97%
Fundamentals
Market Cap ($ Mn)
3,151
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-190.70%
ROCE
-61.41%
EPS (TTM)
$-1.50
Investment Returns
1 Week
-7.40%
1 Month
-2.68%
3 Months
-27.17%
6 Months
-48.94%
9 Months
-38.45%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
9Nov
FDA accepts Celcuity's sNDA for REVTORPYK with 2027 review date
FDA accepted sNDA for REVTORPYK targeting PIK3CA-mutant breast cancer. PDUFA goal date set for June 25, 2027. Submission based on Phase 3 VIKTORIA-1 trial data. Follows July 2026 approval for non-mutant indication.
3 days ago
9Nov
HC Wainwright maintains Buy on Celcuity, cuts price target to $150
HC Wainwright & Co. maintains a Buy rating on Celcuity. Price target lowered from $155 to $150. Revision attributed to analyst Swayampakula Ramakanth.
3 days ago
6Nov
Guggenheim maintains Buy on Celcuity, lowers price target to $169
Guggenheim maintains a Buy rating on Celcuity Inc. Price target lowered from $171 to $169. Analyst Michael Schmidt leads the coverage update.
6 days ago
6Nov
Celcuity Q3FY26 Results: Net loss widens to $73.3 million, no revenue recognized
Celcuity Inc. reported a net loss of $73.3 million for Q3FY26, widening from $43.8 million in the prior year. No revenue was recognized as Retropic shipments began on September 30, with delivery occurring after quarter-end. Operating expenses rose to $77.3 million, driven by a $27.4 million increase in SG&A for commercialization efforts. Cash reserves increased to $642.7 million following a convertible note offering, funding operations through 2029. Retropic secured coverage for 91% of US commercial and Medicare lives, with early orders from 78% of top strategic accounts.
7 days ago
21Oct
TD Cowen reiterates Buy on Celcuity with $145 price target
TD Cowen analyst Tara Bancroft reiterated a Buy rating on Celcuity Inc. Price target remains unchanged at $145 per share. The update reflects consistent institutional coverage without new financial disclosures.
22 days ago
2Oct
Celcuity appoints David Gryska to board amid commercial transition
Celcuity appointed David W. Gryska to its Board of Directors. Gryska brings over 35 years of life sciences financial leadership experience. Appointment follows first FDA approval for REVTORPYK (gedatolisib). Gryska previously served as CFO at Incyte Corporation and Celgene Corporation.
